Michael Chisamore
Executive Director Scientist), Oncology Clinical Research, Early Development Merck
Seminars
Friday 27th February 2026
Competing in a Crowded ADC Landscape: What Does True Clinical Differentiation Look Like in Today’s ADC Market?
3:10 pm
- How can we improve toxicity profiles and delivery better than Enhertu?
- What and how are leaders achieving efficacy beyond a monospecific with a BsAb and BsADCs
- Leveraging synergy between biology of targets and binding events to improve ADC performance
